0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Hemophilia Gene Therapy Market Research Report 2026
Published Date: 2026-01-23
|
Report Code: QYRE-Auto-13B13011
Home | Market Reports
Global Hemophilia Gene Therapy Sales Market Report 2023
BUY CHAPTERS

Global Hemophilia Gene Therapy Market Research Report 2026

Code: QYRE-Auto-13B13011
Report
2026-01-23
Pages:106
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Hemophilia Gene Therapy Market

The global Hemophilia Gene Therapy market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.
This report delivers a comprehensive overview of the global Hemophilia Gene Therapy market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hemophilia Gene Therapy. The Hemophilia Gene Therapy market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Hemophilia Gene Therapy market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Hemophilia Gene Therapy manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Hemophilia Gene Therapy Market Report

Report Metric Details
Report Name Hemophilia Gene Therapy Market
Segment by Type
  • Hemophilia A
  • Hemophilia B
Segment by Application
  • Hemophilia A Gene Therapy
  • Hemophilia B Gene Therapy
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for Hemophilia Gene Therapy companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Hemophilia Gene Therapy Market report?

Ans: The main players in the Hemophilia Gene Therapy Market are Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics

What are the Application segmentation covered in the Hemophilia Gene Therapy Market report?

Ans: The Applications covered in the Hemophilia Gene Therapy Market report are Hemophilia A Gene Therapy, Hemophilia B Gene Therapy

What are the Type segmentation covered in the Hemophilia Gene Therapy Market report?

Ans: The Types covered in the Hemophilia Gene Therapy Market report are Hemophilia A, Hemophilia B

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hemophilia Gene Therapy Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Hemophilia A
1.2.3 Hemophilia B
1.3 Market by Application
1.3.1 Global Hemophilia Gene Therapy Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Hemophilia A Gene Therapy
1.3.3 Hemophilia B Gene Therapy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hemophilia Gene Therapy Market Perspective (2021–2032)
2.2 Global Hemophilia Gene Therapy Growth Trends by Region
2.2.1 Global Hemophilia Gene Therapy Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Hemophilia Gene Therapy Historic Market Size by Region (2021–2026)
2.2.3 Hemophilia Gene Therapy Forecasted Market Size by Region (2027–2032)
2.3 Hemophilia Gene Therapy Market Dynamics
2.3.1 Hemophilia Gene Therapy Industry Trends
2.3.2 Hemophilia Gene Therapy Market Drivers
2.3.3 Hemophilia Gene Therapy Market Challenges
2.3.4 Hemophilia Gene Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hemophilia Gene Therapy Players by Revenue
3.1.1 Global Top Hemophilia Gene Therapy Players by Revenue (2021–2026)
3.1.2 Global Hemophilia Gene Therapy Revenue Market Share by Players (2021–2026)
3.2 Global Top Hemophilia Gene Therapy Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Hemophilia Gene Therapy Revenue
3.4 Global Hemophilia Gene Therapy Market Concentration Ratio
3.4.1 Global Hemophilia Gene Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hemophilia Gene Therapy Revenue in 2025
3.5 Global Key Players of Hemophilia Gene Therapy Head Offices and Areas Served
3.6 Global Key Players of Hemophilia Gene Therapy, Products and Applications
3.7 Global Key Players of Hemophilia Gene Therapy, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Hemophilia Gene Therapy Breakdown Data by Type
4.1 Global Hemophilia Gene Therapy Historic Market Size by Type (2021–2026)
4.2 Global Hemophilia Gene Therapy Forecasted Market Size by Type (2027–2032)
5 Hemophilia Gene Therapy Breakdown Data by Application
5.1 Global Hemophilia Gene Therapy Historic Market Size by Application (2021–2026)
5.2 Global Hemophilia Gene Therapy Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Hemophilia Gene Therapy Market Size (2021–2032)
6.2 North America Hemophilia Gene Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Hemophilia Gene Therapy Market Size by Country (2021–2026)
6.4 North America Hemophilia Gene Therapy Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hemophilia Gene Therapy Market Size (2021–2032)
7.2 Europe Hemophilia Gene Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Hemophilia Gene Therapy Market Size by Country (2021–2026)
7.4 Europe Hemophilia Gene Therapy Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Hemophilia Gene Therapy Market Size (2021–2032)
8.2 Asia-Pacific Hemophilia Gene Therapy Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Hemophilia Gene Therapy Market Size by Region (2021–2026)
8.4 Asia-Pacific Hemophilia Gene Therapy Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Hemophilia Gene Therapy Market Size (2021–2032)
9.2 Latin America Hemophilia Gene Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Hemophilia Gene Therapy Market Size by Country (2021–2026)
9.4 Latin America Hemophilia Gene Therapy Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hemophilia Gene Therapy Market Size (2021–2032)
10.2 Middle East & Africa Hemophilia Gene Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2021–2026)
10.4 Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Spark Therapeutics
11.1.1 Spark Therapeutics Company Details
11.1.2 Spark Therapeutics Business Overview
11.1.3 Spark Therapeutics Hemophilia Gene Therapy Introduction
11.1.4 Spark Therapeutics Revenue in Hemophilia Gene Therapy Business (2021–2026)
11.1.5 Spark Therapeutics Recent Development
11.2 Ultragenyx
11.2.1 Ultragenyx Company Details
11.2.2 Ultragenyx Business Overview
11.2.3 Ultragenyx Hemophilia Gene Therapy Introduction
11.2.4 Ultragenyx Revenue in Hemophilia Gene Therapy Business (2021–2026)
11.2.5 Ultragenyx Recent Development
11.3 Shire PLC
11.3.1 Shire PLC Company Details
11.3.2 Shire PLC Business Overview
11.3.3 Shire PLC Hemophilia Gene Therapy Introduction
11.3.4 Shire PLC Revenue in Hemophilia Gene Therapy Business (2021–2026)
11.3.5 Shire PLC Recent Development
11.4 Sangamo Therapeutics
11.4.1 Sangamo Therapeutics Company Details
11.4.2 Sangamo Therapeutics Business Overview
11.4.3 Sangamo Therapeutics Hemophilia Gene Therapy Introduction
11.4.4 Sangamo Therapeutics Revenue in Hemophilia Gene Therapy Business (2021–2026)
11.4.5 Sangamo Therapeutics Recent Development
11.5 Bioverativ
11.5.1 Bioverativ Company Details
11.5.2 Bioverativ Business Overview
11.5.3 Bioverativ Hemophilia Gene Therapy Introduction
11.5.4 Bioverativ Revenue in Hemophilia Gene Therapy Business (2021–2026)
11.5.5 Bioverativ Recent Development
11.6 BioMarin
11.6.1 BioMarin Company Details
11.6.2 BioMarin Business Overview
11.6.3 BioMarin Hemophilia Gene Therapy Introduction
11.6.4 BioMarin Revenue in Hemophilia Gene Therapy Business (2021–2026)
11.6.5 BioMarin Recent Development
11.7 uniQure
11.7.1 uniQure Company Details
11.7.2 uniQure Business Overview
11.7.3 uniQure Hemophilia Gene Therapy Introduction
11.7.4 uniQure Revenue in Hemophilia Gene Therapy Business (2021–2026)
11.7.5 uniQure Recent Development
11.8 Freeline Therapeutics
11.8.1 Freeline Therapeutics Company Details
11.8.2 Freeline Therapeutics Business Overview
11.8.3 Freeline Therapeutics Hemophilia Gene Therapy Introduction
11.8.4 Freeline Therapeutics Revenue in Hemophilia Gene Therapy Business (2021–2026)
11.8.5 Freeline Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Hemophilia Gene Therapy Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of Hemophilia A
 Table 3. Key Players of Hemophilia B
 Table 4. Global Hemophilia Gene Therapy Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 5. Global Hemophilia Gene Therapy Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 6. Global Hemophilia Gene Therapy Market Size by Region (US$ Million), 2021–2026
 Table 7. Global Hemophilia Gene Therapy Market Share by Region (2021–2026)
 Table 8. Global Hemophilia Gene Therapy Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 9. Global Hemophilia Gene Therapy Market Share by Region (2027–2032)
 Table 10. Hemophilia Gene Therapy Market Trends
 Table 11. Hemophilia Gene Therapy Market Drivers
 Table 12. Hemophilia Gene Therapy Market Challenges
 Table 13. Hemophilia Gene Therapy Market Restraints
 Table 14. Global Hemophilia Gene Therapy Revenue by Players (US$ Million), 2021–2026
 Table 15. Global Hemophilia Gene Therapy Market Share by Players (2021–2026)
 Table 16. Global Top Hemophilia Gene Therapy Players by Tier (Tier 1, Tier 2, and Tier 3), based on Hemophilia Gene Therapy Revenue, 2025
 Table 17. Ranking of Global Top Hemophilia Gene Therapy Companies by Revenue (US$ Million) in 2025
 Table 18. Global 5 Largest Players Market Share by Hemophilia Gene Therapy Revenue (CR5 and HHI), 2021–2026
 Table 19. Global Key Players of Hemophilia Gene Therapy, Headquarters and Area Served
 Table 20. Global Key Players of Hemophilia Gene Therapy, Products and Applications
 Table 21. Global Key Players of Hemophilia Gene Therapy, Date of General Availability (GA)
 Table 22. Mergers and Acquisitions, Expansion Plans
 Table 23. Global Hemophilia Gene Therapy Market Size by Type (US$ Million), 2021–2026
 Table 24. Global Hemophilia Gene Therapy Revenue Market Share by Type (2021–2026)
 Table 25. Global Hemophilia Gene Therapy Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 26. Global Hemophilia Gene Therapy Revenue Market Share by Type (2027–2032)
 Table 27. Global Hemophilia Gene Therapy Market Size by Application (US$ Million), 2021–2026
 Table 28. Global Hemophilia Gene Therapy Revenue Market Share by Application (2021–2026)
 Table 29. Global Hemophilia Gene Therapy Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 30. Global Hemophilia Gene Therapy Revenue Market Share by Application (2027–2032)
 Table 31. North America Hemophilia Gene Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 32. North America Hemophilia Gene Therapy Market Size by Country (US$ Million), 2021–2026
 Table 33. North America Hemophilia Gene Therapy Market Size by Country (US$ Million), 2027–2032
 Table 34. Europe Hemophilia Gene Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 35. Europe Hemophilia Gene Therapy Market Size by Country (US$ Million), 2021–2026
 Table 36. Europe Hemophilia Gene Therapy Market Size by Country (US$ Million), 2027–2032
 Table 37. Asia-Pacific Hemophilia Gene Therapy Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 38. Asia-Pacific Hemophilia Gene Therapy Market Size by Region (US$ Million), 2021–2026
 Table 39. Asia-Pacific Hemophilia Gene Therapy Market Size by Region (US$ Million), 2027–2032
 Table 40. Latin America Hemophilia Gene Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 41. Latin America Hemophilia Gene Therapy Market Size by Country (US$ Million), 2021–2026
 Table 42. Latin America Hemophilia Gene Therapy Market Size by Country (US$ Million), 2027–2032
 Table 43. Middle East & Africa Hemophilia Gene Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 44. Middle East & Africa Hemophilia Gene Therapy Market Size by Country (US$ Million), 2021–2026
 Table 45. Middle East & Africa Hemophilia Gene Therapy Market Size by Country (US$ Million), 2027–2032
 Table 46. Spark Therapeutics Company Details
 Table 47. Spark Therapeutics Business Overview
 Table 48. Spark Therapeutics Hemophilia Gene Therapy Product
 Table 49. Spark Therapeutics Revenue in Hemophilia Gene Therapy Business (US$ Million), 2021–2026
 Table 50. Spark Therapeutics Recent Development
 Table 51. Ultragenyx Company Details
 Table 52. Ultragenyx Business Overview
 Table 53. Ultragenyx Hemophilia Gene Therapy Product
 Table 54. Ultragenyx Revenue in Hemophilia Gene Therapy Business (US$ Million), 2021–2026
 Table 55. Ultragenyx Recent Development
 Table 56. Shire PLC Company Details
 Table 57. Shire PLC Business Overview
 Table 58. Shire PLC Hemophilia Gene Therapy Product
 Table 59. Shire PLC Revenue in Hemophilia Gene Therapy Business (US$ Million), 2021–2026
 Table 60. Shire PLC Recent Development
 Table 61. Sangamo Therapeutics Company Details
 Table 62. Sangamo Therapeutics Business Overview
 Table 63. Sangamo Therapeutics Hemophilia Gene Therapy Product
 Table 64. Sangamo Therapeutics Revenue in Hemophilia Gene Therapy Business (US$ Million), 2021–2026
 Table 65. Sangamo Therapeutics Recent Development
 Table 66. Bioverativ Company Details
 Table 67. Bioverativ Business Overview
 Table 68. Bioverativ Hemophilia Gene Therapy Product
 Table 69. Bioverativ Revenue in Hemophilia Gene Therapy Business (US$ Million), 2021–2026
 Table 70. Bioverativ Recent Development
 Table 71. BioMarin Company Details
 Table 72. BioMarin Business Overview
 Table 73. BioMarin Hemophilia Gene Therapy Product
 Table 74. BioMarin Revenue in Hemophilia Gene Therapy Business (US$ Million), 2021–2026
 Table 75. BioMarin Recent Development
 Table 76. uniQure Company Details
 Table 77. uniQure Business Overview
 Table 78. uniQure Hemophilia Gene Therapy Product
 Table 79. uniQure Revenue in Hemophilia Gene Therapy Business (US$ Million), 2021–2026
 Table 80. uniQure Recent Development
 Table 81. Freeline Therapeutics Company Details
 Table 82. Freeline Therapeutics Business Overview
 Table 83. Freeline Therapeutics Hemophilia Gene Therapy Product
 Table 84. Freeline Therapeutics Revenue in Hemophilia Gene Therapy Business (US$ Million), 2021–2026
 Table 85. Freeline Therapeutics Recent Development
 Table 86. Research Programs/Design for This Report
 Table 87. Key Data Information from Secondary Sources
 Table 88. Key Data Information from Primary Sources
 Table 89. Authors List of This Report


List of Figures
 Figure 1. Hemophilia Gene Therapy Picture
 Figure 2. Global Hemophilia Gene Therapy Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global Hemophilia Gene Therapy Market Share by Type: 2025 vs 2032
 Figure 4. Hemophilia A Features
 Figure 5. Hemophilia B Features
 Figure 6. Global Hemophilia Gene Therapy Market Size by Application (US$ Million), 2021–2032
 Figure 7. Global Hemophilia Gene Therapy Market Share by Application: 2025 vs 2032
 Figure 8. Hemophilia A Gene Therapy Case Studies
 Figure 9. Hemophilia B Gene Therapy Case Studies
 Figure 10. Hemophilia Gene Therapy Report Years Considered
 Figure 11. Global Hemophilia Gene Therapy Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 12. Global Hemophilia Gene Therapy Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 13. Global Hemophilia Gene Therapy Market Share by Region: 2025 vs 2032
 Figure 14. Global Hemophilia Gene Therapy Market Share by Players in 2025
 Figure 15. Global Hemophilia Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 16. The Top 10 and 5 Players Market Share by Hemophilia Gene Therapy Revenue in 2025
 Figure 17. North America Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 18. North America Hemophilia Gene Therapy Market Share by Country (2021–2032)
 Figure 19. United States Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 20. Canada Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 21. Europe Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 22. Europe Hemophilia Gene Therapy Market Share by Country (2021–2032)
 Figure 23. Germany Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 24. France Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 25. U.K. Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 26. Italy Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 27. Russia Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. Ireland Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. Asia-Pacific Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 30. Asia-Pacific Hemophilia Gene Therapy Market Share by Region (2021–2032)
 Figure 31. China Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 32. Japan Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 33. South Korea Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 34. Southeast Asia Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 35. India Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. Australia & New Zealand Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. Latin America Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 38. Latin America Hemophilia Gene Therapy Market Share by Country (2021–2032)
 Figure 39. Mexico Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 40. Brazil Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 41. Middle East & Africa Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 42. Middle East & Africa Hemophilia Gene Therapy Market Share by Country (2021–2032)
 Figure 43. Israel Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 44. Saudi Arabia Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 45. UAE Hemophilia Gene Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 46. Spark Therapeutics Revenue Growth Rate in Hemophilia Gene Therapy Business (2021–2026)
 Figure 47. Ultragenyx Revenue Growth Rate in Hemophilia Gene Therapy Business (2021–2026)
 Figure 48. Shire PLC Revenue Growth Rate in Hemophilia Gene Therapy Business (2021–2026)
 Figure 49. Sangamo Therapeutics Revenue Growth Rate in Hemophilia Gene Therapy Business (2021–2026)
 Figure 50. Bioverativ Revenue Growth Rate in Hemophilia Gene Therapy Business (2021–2026)
 Figure 51. BioMarin Revenue Growth Rate in Hemophilia Gene Therapy Business (2021–2026)
 Figure 52. uniQure Revenue Growth Rate in Hemophilia Gene Therapy Business (2021–2026)
 Figure 53. Freeline Therapeutics Revenue Growth Rate in Hemophilia Gene Therapy Business (2021–2026)
 Figure 54. Bottom-up and Top-down Approaches for This Report
 Figure 55. Data Triangulation
 Figure 56. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Novocure

SIMILAR REPORTS